Momenta Pharmaceuticals Inc. (MNTA)
-NasdaqGS 13.31 
0.05(0.38%) 12:06PM EDT - Nasdaq Real Time Price
| Prev Close: | 13.26 |
|---|
| Open: | 13.03 |
|---|
| Bid: | 13.32 x 100 |
|---|
| Ask: | 13.33 x 200 |
|---|
| 1y Target Est: | 14.80 |
|---|
| Beta: | 2.28 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 13.03 - 13.34 |
|---|
| 52wk Range: | 10.05 - 17.09 |
|---|
| Volume: | 73,286 |
|---|
| Avg Vol (3m): | 308,390 |
|---|
| Market Cap: | 675.10M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.54 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Momenta Pharmaceuticals Management Presents at 2013 UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Wed, May 22)
- Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industryat Seeking Alpha(Wed, May 22)
- MOMENTA PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Momenta Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Thu, May 16)
- Momenta Pharmaceuticals (MNTA) Shares Cross Above 200 DMAat TheStreet(Mon, May 13)
- MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor ConferencesGlobeNewswire(Thu, May 9)
- 5 Names Seeing Bullish Options Flowat TheStreet(Thu, May 2)
- Big Generic Drug Players See Best Topline Growth Rates in Emerging Markets: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street TranscriptWall Street Transcript(Thu, May 2)
- Momenta Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Oversold Conditions For Momenta Pharmaceuticals (MNTA)at TheStreet(Tue, Apr 30)
- Momenta Pharmaceuticals Earnings: Here’s Why Shares are Down Nowat Wall St. Cheat Sheet(Tue, Apr 30)
- Momenta Pharmaceuticals Reports First Quarter 2013 Financial ResultsGlobeNewswire(Tue, Apr 30)
- Q1 2013 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market OpenCCBN(Tue, Apr 30)
- MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aEDGAR Online(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 14.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.46 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules.
View More